Apellis Pharmaceuticals, Inc.APLS決算レポート
Nasdaq · ヘルスケア · 医薬製剤
アペリスファーマシューティカルズは補体系を調節する標的治療薬の開発に注力する臨床段階のバイオ医薬品企業です。加齢黄斑変性に続発する地図状萎縮をはじめとする眼科疾患、希少血液疾患、自己免疫疾患を主な適応とし、米国と欧州を中心に事業を展開しています。
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Wellington Management Group LLP | 12.81% | 15.6M | ▼ -1.10pp | 2024-11-08 |
| Avoro Capital Advisors LLC | 9.90% | 13.4M | — | 2024-02-14 |
| EcoR1 Capital, LLC | 9.40% | 11.2M | ▲ +4.00pp | 2024-02-14 |
| The Vanguard Group | 8.06% | 9.6M | — | 2024-02-13 |
| BlackRock, Inc. | 5.10% | 6.2M | 変動なし | 2024-11-08 |
| Deep Track Capital, LP | 4.82% | 6.0M | ▼ -0.18pp | 2024-11-22 |
| T. Rowe Price Investment Management, Inc. | 2.50% | 3.0M | ▼ -2.80pp | 2024-11-14 |
インサイダー取引
Net 90d: −$8.2K · buys $0 / sells $8.2K期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-17 | Sullivan Timothy Eugene | Chief Financial Officer | Gift | 11.1K | $0.00 | $0 |
| 2026-04-17 | Sullivan Timothy Eugene | Chief Financial Officer | Gift | 11.1K | $0.00 | $0 |
| 2026-04-06 | O'Brien Stephanie Monaghan | Director | Other | 5.8K | $0.00 | $0 |
| 2026-03-11 | Cedric Francois | Chief Executive Officer | Gift | 64.9K | $0.00 | $0 |
| 2026-03-11 | Cedric Francois | Chief Executive Officer | Gift | 64.9K | $0.00 | $0 |
| 2026-02-27 | Mikael Dolsten | Director | Grant | 14.3K | $0.00 | $0 |
| 2026-02-11 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell (open market) | 368 | $22.15 | $8.2K |
| 2026-02-03 | Cedric Francois | Chief Executive Officer | Option exercise | 8.8K | $3.76 | $33.2K |
1–8 of 8